# Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids

> **NCT01563913** · PHASE1 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 33 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Docosahexaenoic Acid (DHA)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01563913
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2018-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01563913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01563913, "Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01563913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*